278 related articles for article (PubMed ID: 24118504)
1. Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer.
Zhao L; Yasumoto K; Kawashima A; Nakagawa T; Takeuchi S; Yamada T; Matsumoto K; Yonekura K; Yoshie O; Yano S
Cancer Sci; 2013 Dec; 104(12):1640-6. PubMed ID: 24118504
[TBL] [Abstract][Full Text] [Related]
2. Dual blockade of MET and VEGFR2 signaling pathways as a potential therapeutic maneuver for peritoneal carcinomatosis in scirrhous gastric cancer.
Kasai S; Kuwayama N; Motoo Y; Kawashima A; Matsumoto K; Yano S; Matsushima K; Yasumoto K
Biochem Biophys Res Commun; 2022 Apr; 600():80-86. PubMed ID: 35196631
[TBL] [Abstract][Full Text] [Related]
3. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
Knowles LM; Stabile LP; Egloff AM; Rothstein ME; Thomas SM; Gubish CT; Lerner EC; Seethala RR; Suzuki S; Quesnelle KM; Morgan S; Ferris RL; Grandis JR; Siegfried JM
Clin Cancer Res; 2009 Jun; 15(11):3740-50. PubMed ID: 19470725
[TBL] [Abstract][Full Text] [Related]
4. The EGFR ligands amphiregulin and heparin-binding egf-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer.
Yasumoto K; Yamada T; Kawashima A; Wang W; Li Q; Donev IS; Tacheuchi S; Mouri H; Yamashita K; Ohtsubo K; Yano S
Clin Cancer Res; 2011 Jun; 17(11):3619-30. PubMed ID: 21482691
[TBL] [Abstract][Full Text] [Related]
5. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
[TBL] [Abstract][Full Text] [Related]
6. Influence of hepatocyte growth factor secreted from fibroblasts on the growth and invasion of scirrhous gastric cancer.
Murakami N; Koufuji K; Shirouzu K
Int Surg; 2001; 86(3):151-7. PubMed ID: 11996071
[TBL] [Abstract][Full Text] [Related]
7. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
Nakade J; Takeuchi S; Nakagawa T; Ishikawa D; Sano T; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Matsumoto K; Yonekura K; Yano S
J Thorac Oncol; 2014 Jun; 9(6):775-83. PubMed ID: 24828661
[TBL] [Abstract][Full Text] [Related]
8. Crizotinib, a MET inhibitor, prevents peritoneal dissemination in pancreatic cancer.
Takiguchi S; Inoue K; Matsusue K; Furukawa M; Teramoto N; Iguchi H
Int J Oncol; 2017 Jul; 51(1):184-192. PubMed ID: 28498406
[TBL] [Abstract][Full Text] [Related]
9. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
[TBL] [Abstract][Full Text] [Related]
10. A novel transforming growth factor beta receptor kinase inhibitor, A-77, prevents the peritoneal dissemination of scirrhous gastric carcinoma.
Kawajiri H; Yashiro M; Shinto O; Nakamura K; Tendo M; Takemura S; Node M; Hamashima Y; Kajimoto T; Sawada T; Ohira M; Hirakawa K
Clin Cancer Res; 2008 May; 14(9):2850-60. PubMed ID: 18451253
[TBL] [Abstract][Full Text] [Related]
11. Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment.
Kwon Y; Smith BD; Zhou Y; Kaufman MD; Godwin AK
Oncogene; 2015 Jan; 34(2):144-53. PubMed ID: 24362531
[TBL] [Abstract][Full Text] [Related]
12. Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer.
Yasumoto K; Koizumi K; Kawashima A; Saitoh Y; Arita Y; Shinohara K; Minami T; Nakayama T; Sakurai H; Takahashi Y; Yoshie O; Saiki I
Cancer Res; 2006 Feb; 66(4):2181-7. PubMed ID: 16489019
[TBL] [Abstract][Full Text] [Related]
13. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
[TBL] [Abstract][Full Text] [Related]
14. Cancer-associated fibroblasts might sustain the stemness of scirrhous gastric cancer cells via transforming growth factor-β signaling.
Hasegawa T; Yashiro M; Nishii T; Matsuoka J; Fuyuhiro Y; Morisaki T; Fukuoka T; Shimizu K; Shimizu T; Miwa A; Hirakawa K
Int J Cancer; 2014 Apr; 134(8):1785-95. PubMed ID: 24155219
[TBL] [Abstract][Full Text] [Related]
15. A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer.
Nakamura K; Yashiro M; Matsuoka T; Tendo M; Shimizu T; Miwa A; Hirakawa K
Gastroenterology; 2006 Nov; 131(5):1530-41. PubMed ID: 17101326
[TBL] [Abstract][Full Text] [Related]
16. Preclinical study of a "tailor-made" combination of NK4-expressing gene therapy and gefitinib (ZD1839, Iressa) for disseminated peritoneal scirrhous gastric cancer.
Namiki Y; Namiki T; Yoshida H; Date M; Yashiro M; Matsumoto K; Nakamura T; Yanagihara K; Tada N; Satoi J; Fujise K
Int J Cancer; 2006 Mar; 118(6):1545-55. PubMed ID: 16206271
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effect of a selective cyclooxygenase inhibitor on the invasion-stimulating activity of orthotopic fibroblasts for scirrhous gastric cancer cells.
Tendo M; Yashiro M; Nakazawa K; Yamada N; Hirakawa K
Cancer Sci; 2005 Jul; 96(7):451-5. PubMed ID: 16053517
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
19. HIF-1α is a crucial factor in the development of peritoneal dissemination via natural metastatic routes in scirrhous gastric cancer.
Miyake S; Kitajima Y; Nakamura J; Kai K; Yanagihara K; Tanaka T; Hiraki M; Miyazaki K; Noshiro H
Int J Oncol; 2013 Nov; 43(5):1431-40. PubMed ID: 23970191
[TBL] [Abstract][Full Text] [Related]
20. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
Chen X; Zhou JY; Zhao J; Chen JJ; Ma SN; Zhou JY
Anticancer Drugs; 2013 Nov; 24(10):1039-46. PubMed ID: 23962905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
